The World Health Organization began a clinical trial in the eastern Democratic Republic of Congo on Thursday to test two potential Ebola treatments [1].

The trial is a critical effort to find an effective therapeutic response to the Bundibugyo species of Ebola, which continues to spread across the region. With more than 1,000 reported cases in the current outbreak [2], the search for a proven medical intervention is urgent to reduce mortality rates.

WHO chief Tedros Adhanom Ghebreyesus said the trial evaluates the monoclonal antibody MBP134 and the antiviral drug remdesivir [1]. These two experimental treatments [1] are being tested separately and in combination to determine which approach provides the best patient outcomes.

Medical teams in the DRC are managing the enrollment process for the study. Tedros Adhanom Ghebreyesus said, "Patients who enrol in the trial will receive comprehensive supportive care and close follow up" [3].

The trial focuses on the Bundibugyo strain, which differs from other species of the virus and requires specific therapeutic targeting. By testing both a monoclonal antibody and an antiviral drug, the WHO aims to establish a standardized treatment protocol for future outbreaks of this specific strain.

The deployment of these treatments represents a coordinated international response to the health crisis in the DRC. The trial seeks to determine if the combined use of MBP134 and remdesivir offers a synergistic effect that increases survival rates compared to using either drug alone [1].

“The trial tests the monoclonal antibody MBP134 and the antiviral drug remdesivir”

The launch of this trial indicates that existing Ebola treatments may be insufficient for the Bundibugyo strain. By testing both monoclonal antibodies and antivirals, the WHO is attempting to create a versatile toolkit for a virus known for high fatality rates, potentially shifting the medical response from basic supportive care to targeted therapy.